Effect on the Electrocardiographic QT Interval Corrected for Heart Rate (QTc) in Healthy Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

The purpose of this study is to determine the effect of BMS-708163 on the QTc interval (QT interval corrected for heart rate).

Key facts

Study ID

NCT00979316

Run by

Bristol-Myers Squibb

People needed

62

Starts

2009-09-01

Expected to finish

2010-02-01

Last updated by the study team

2011-01-07

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Body Mass Index (BMI) of 18 to 32 kg/m², inclusive.
• Women who are not of childbearing potential (ie, who are postmenopausal or surgically sterile) and men, ages 18 to 55
• Healthy subjects

You may not qualify if…

• History of cardiac arrhythmias or palpitations associated with presyncope or syncope, or history of unexplained syncope
• Sexually active fertile men not using effective birth control (double barrier) if their partners are WOCBP
• Women who are pregnant or breastfeeding
• History of allergy or intolerance to moxifloxacin or any member of the quinolone class of antimicrobial agents
• History of hypokalemia, history or family history of prolonged QT interval, or family history of sudden cardiac death at a young age
• Any clinically significant ECG abnormality
• History of seizure disorders
• History of drowning survival

Where it is running

• Mds Pharma Services (Us), Inc — Tempe, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.